[16] [17] Naturally produced GLP-1 has a very short half-life of approximately 23 minutes because it is rapidly degraded by the enzyme dipeptidyl peptidase-4 (DPP-4)
Liraglutide, semaglutide and tirzepatide are incretin-based therapies currently approved by FDA for the management of obesity, while triple GIPR/GCGR/GLP-1R agonist retatrutide (LY3437943), the cagrilintide/semaglutide (CagriSema) 2.4 mg combination, high-dose oral semaglutide, and oral orforglipron are in advanced stages of development
Epigenetic regulation of IPF fibroblast phenotype by glutaminolysis
Salamun V, Jensterle M, Janez A, Bokal EV
We performed additional time-based analysis for the risk of DKA between the two cohorts
As with any GLP-1 medication, side effects such as nausea, fatigue, and gastrointestinal discomfort are possible